Intermediate hyperglycaemia and 10-year mortality in resource-constrained settings: the PERU MIGRANT Study
- PMID: 32181918
- PMCID: PMC7649719
- DOI: 10.1111/dme.14298
Intermediate hyperglycaemia and 10-year mortality in resource-constrained settings: the PERU MIGRANT Study
Abstract
Aim: To determine whether intermediate hyperglycaemia, defined by fasting plasma glucose and HbA1c criteria, is associated with mortality in a 10-year cohort of people in a Latin American country.
Methods: Analysis of the PERU MIGRANT Study was conducted in three different population groups (rural, rural-to-urban migrant, and urban). The baseline assessment was conducted in 2007/2008, with follow-up assessment in 2018. The outcome was all-cause mortality, and the exposure was intermediate hyperglycaemia, using three definitions: (1) impaired fasting glucose, defined according to American Diabetes Association criteria [fasting plasma glucose 5.6-6.9 mmol/l (100-125 mg/dl)]; (2) intermediate hyperglycaemia defined according to American Diabetes Association criteria [HbA1c levels 39-46 mmol/mol (5.7-6.4%)]; and (3) intermediate hyperglycaemia defined according to the International Expert Committee criteria [HbA1c levels 42-46 mmol/mol (6.0-6.4%)]. Crude and adjusted hazard ratios and 95% CIs were estimated using Cox proportional hazard models.
Results: At baseline, the mean (sd) age of the study population was 47.8 (11.9) years and 52.5% of the cohort were women. The study cohort was divided into population groups as follows: 207 people (20.0%) in the rural population group, 583 (59.7%) in the rural-to-urban migrant group and 198 (20.3%) in the urban population group. The prevalence of intermediate hyperglycaemia was: 6%, 12.9% and 38.5% according to the American Diabetes Association impaired fasting glucose definition, the International Expert Committee HbA1c -based definition and the American Diabetes Association HbA1c -based definition, respectively, and the mortality rate after 10 years was 63/976 (7%). Intermediate hyperglycaemia was associated with all-cause mortality using the HbA1c -based definitions in the crude models [hazard ratios 2.82 (95% CI 1.59-4.99) according to the American Diabetes Association and 2.92 (95% CI 1.62-5.28) according to the International Expert Committee], whereas American Diabetes Association-defined impaired fasting glucose was not [hazard ratio 0.84 (95% CI 0.26-2.68)]. In the adjusted model, however, only the American Diabetes Association HbA1c -based definition was associated with all-cause mortality [hazard ratio 1.91 (95% CI 1.03-3.53)], whereas the International Expert Committee HbA1c -based and American Diabetes Association impaired fasting glucose-based definitions were not [hazard ratios 1.42 (95% CI 0.75-2.68) and 1.09 (95% CI 0.33-3.63), respectively].
Conclusions: Intermediate hyperglycaemia defined using the American Diabetes Association HbA1c criteria was associated with an elevated mortality rate after 10 years in a cohort from Peru. HbA1c appears to be a factor associated with mortality in this Peruvian population.
© 2020 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.
References
-
- World Health Organization (WHO) . Global Report on Diabetes. Geneva: WHO, 2016.
-
- Schmidt MI, Bracco PA, Yudkin JS, Bensenor IM, Griep RH, Barreto SM et al Intermediate hyperglycaemia to predict progression to type 2 diabetes (ELSA‐Brasil): an occupational cohort study in Brazil. Lancet Diabetes Endocrinol 2019; 7: 267–277. - PubMed
-
- Yudkin JS. "Prediabetes": Are There Problems With This Label? Yes, the Label Creates Further Problems! Diabetes Care 2016; 39: 1468–1471. - PubMed
-
- Tancredi M, Rosengren A, Svensson AM, Kosiborod M, Pivodic A, Gudbjornsdottir S et al Excess Mortality among Persons with Type 2 Diabetes. N Engl J Med 2015; 373: 1720–1732. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- 5U01HL114180/National Heart, Lung and Blood Institute/International
- 205177/Z/16/Z/WT_/Wellcome Trust/United Kingdom
- MR/M007405/1/MRC_/Medical Research Council/United Kingdom
- 1U19MH098780/MH/NIMH NIH HHS/United States
- D71TW010877/Fogarty International Centre/International
- HHSN268200900033C/HL/NHLBI NIH HHS/United States
- D71 TW010877/TW/FIC NIH HHS/United States
- 294834/Z ISSF ICL/Welcome Trust-Imperial College/International
- 1UM1HL134590/National Heart, Lung and Blood Institute/International
- IAI CRN3036/Inter-American Institute for Global Change Research/International
- P20 CA217231/CA/NCI NIH HHS/United States
- 40P740-160366/SNSF_/Swiss National Science Foundation/Switzerland
- 108167/International Development Research Centre Canada/International
- R21 TW009982/TW/FIC NIH HHS/United States
- MR/P02386X/1/MRC_/Medical Research Council/United Kingdom
- HQHSR1206660/Alliance for Health Policy and Systems Research/International
- 106887/International Development Research Centre Canada/International
- R21TW009982/Fogarty International Centre/International
- MR/P008984/1/MRC_/Medical Research Council/United Kingdom
- U01 HL114180/HL/NHLBI NIH HHS/United States
- WDF15-1224/World Diabetes Foundation/International
- U19 MH098780/MH/NIMH NIH HHS/United States
- 100693/Z/12/Z/Welcome Trust-Imperial College/International
- MR/P024408/1/MRC_/Medical Research Council/United Kingdom
- UM1 HL134590/HL/NHLBI NIH HHS/United States
- 1P20CA217231/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous